Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 13/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244628 | 0.90 | SCD (0.42) | SCDHDAC1WNT1DYRK1ACLK2 | |
| SCHEMBL244770 | 0.90 | SCD (0.47) | SCDHDAC1WNT1DYRK1ATRPV1 | |
| SCHEMBL1349977 | 0.83 | SCD (0.67) | SCDHDAC1KDM4EALDH1A1 | |
| SCHEMBL243757 | 0.76 | SCD (0.76) | SCDHDAC1KDM4EALDH1A1 | |
| SCHEMBL244629 | 0.74 | SCD (0.59) | SCDHDAC1KDM4EALDH1A1 | |
| SCHEMBL243457 | 0.74 | SCD (0.68) | SCDHDAC1KDM4EALDH1A1 | |
| SCHEMBL244519 | 0.73 | SCD (0.78) | SCDKDM4EALDH1A1 | |
| SCHEMBL244645 | 0.72 | SCD (0.65) | SCDHDAC1KDM4EALDH1A1 | |
| SCHEMBL245179 | 0.72 | SCD (0.55) | SCDHDAC1KDM4EALDH1A1 | |
| SCHEMBL244879 | 0.71 | PTGDR2 (0.44) | SCDHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885HDAC1 17/4885WNT1 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.